MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ecco-jcc/jjaf063

Медицинская библиотека · Journal of Crohn's & colitis · 2025

Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis.

Verstockt Bram, Alsoud Dahham, van Oostrom Joep, Verstockt Sare, Smith Jeff, Stylli Jack, Singh Sujay, van Gennep Sara, Rahimian Pejman, Sabino João, Ferrante Marc, Kelman Ariella, Singh Sharat, D'Haens Geert, Vermeire Séverine

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Inflammatory bowel disease management has advanced with therapies like Janus kinase inhibitors (JAKi). Despite their promise, JAKi pharmacokinetic-pharmacodynamic (PK-PD) profiles and tissue-level effects remain underexplored. This study investigates tissue and serum tofacitinib levels, their correlation with therapeutic efficacy, and molecular mechanisms underlying treatment response.

METHODS

Thirty refractory ulcerative colitis (UC) patients receiving tofacitinib were prospectively studied. Tissue biopsies and serum samples were collected pre- and post-induction for PK analysis using liquid chromatography mass spectrometry. RNA sequencing and cytokine profiling were performed on tissue samples to explore molecular responses. Endoscopic improvement was defined as a Mayo endoscopic subscore of 0-1 by week 16.

RESULTS

Tofacitinib tissue concentrations were 25-fold higher than serum levels and significantly correlated (ρ=0.92, P < .001). Responders showed significantly higher tissue drug exposure (1047.5 ng/g vs 467.1 ng/g, P = .02) at the time of endoscopic assessment. Tofacitinib treatment reduced phosphorylated STAT3 (pSTAT3) levels, particularly in responders (P = .02). RNA sequencing revealed gene modules linked to tissue drug and pSTAT3 concentrations. Gene set enrichment analysis showed that these were more frequent in non-responders and associated with JAK-STAT pathways.

CONCLUSIONS

This study underscores the importance of tissue tofacitinib levels in UC treatment efficacy, with pSTAT3 reduction serving as a potential marker of drug efficacy. RNA sequencing identified molecular pathways for potential biomarkers and novel therapeutic targets in tofacitinib non-responders.

Для цитирования: Verstockt Bram, Alsoud Dahham, van Oostrom Joep, Verstockt Sare, Smith Jeff, Stylli Jack, Singh Sujay, van Gennep Sara, Rahimian Pejman, Sabino João, Ferrante Marc, Kelman Ariella, Singh Sharat, D'Haens Geert, Vermeire Séverine. Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis.. Journal of Crohn's & colitis. 2025. DOI: 10.1093/ecco-jcc/jjaf063.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.